Genomics in Assessing Melanoma Prognosis - 26/06/25
, Danny Zakria, MD, MBA b, Lauren DeBusk, MD a, 1, Milaan Shah, MD c, Joshua Burshtein, MD d, Brooke Bartley, MD e, Darrell Rigel, MD, MS a, fRésumé |
Genomic advancements have transformed melanoma prognosis by identifying key genetic alterations that influence disease progression and treatment outcomes. Gene expression profiling (GEP) tests, including the 31-GEP, 11-GEP, and 8-GEP + CP, refine traditional staging by stratifying patients based on recurrence and metastasis risk. These tests enhance clinical decision-making by guiding sentinel lymph node biopsy selection, surveillance intensity, and adjuvant therapy use. Studies confirm their prognostic accuracy, linking GEP results to survival outcomes. Despite their potential, challenges like cost and validation limit widespread adoption. As research progresses, integrating genomic data with traditional staging could further personalize melanoma management.
Le texte complet de cet article est disponible en PDF.Keywords : Melanoma, Genomics, Prognostics, Morbidity, Mortality, Clinical management
Plan
Vol 43 - N° 3
P. 453-460 - juillet 2025 Retour au numéro
Article précédent
- Melanoma Staging Systems
- Redina Bardhi, Aaron Farberg
- The Surgical Management of Cutaneous Melanoma
- Alfredo Siller, Matthew DaCunha, Brett M. Coldiron
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?